Town & Country Bank & Trust CO dba First Bankers Trust CO Buys 1,850 Shares of Stryker Corporation $SYK

Town & Country Bank & Trust CO dba First Bankers Trust CO raised its stake in shares of Stryker Corporation (NYSE:SYK) by 13.0% in the 1st quarter, HoldingsChannel reports. The firm owned 16,063 shares of the medical technology company’s stock after purchasing an additional 1,850 shares during the period. Stryker makes up 1.8% of Town & Country Bank & Trust CO dba First Bankers Trust CO’s portfolio, making the stock its 14th biggest position. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Stryker were worth $5,278,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Sankala Group LLC bought a new stake in shares of Stryker during the 4th quarter worth $26,000. Godfrey Financial Associates Inc. bought a new stake in Stryker during the fourth quarter worth about $26,000. United Financial Planning Group LLC bought a new stake in Stryker during the third quarter worth about $27,000. Atlas Capital Advisors Inc. purchased a new position in shares of Stryker in the 4th quarter worth about $27,000. Finally, DJE Kapital AG purchased a new position in shares of Stryker in the 4th quarter worth about $28,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 0.3%

SYK opened at $308.62 on Monday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The business’s 50-day moving average price is $313.81 and its 200-day moving average price is $341.50. The company has a market cap of $118.31 billion, a P/E ratio of 35.72, a P/E/G ratio of 1.97 and a beta of 0.78.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities analysts expect that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on SYK shares. Leerink Partners decreased their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research note on Friday, May 1st. Wells Fargo & Company reduced their price target on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Evercore set a $355.00 price target on shares of Stryker in a research note on Friday, May 1st. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a research note on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $395.33.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the sale, the vice president directly owned 13,137 shares in the company, valued at approximately $3,728,937.45. This trade represents a 28.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 over the last three months. 4.60% of the stock is owned by company insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.